Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | BLM | P54132 | 1/20 | 0.43 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2852278 | 0.98 | CYP1A2 (0.43) | CYP1A2ALDH1A1USP2LMNATSHR | |
| Hydrochloric Acid SCHEMBL2858088 | 0.91 | CYP1A2 (0.47) | CYP1A2ALDH1A1USP2LMNATSHR | |
| Hydrochloric Acid SCHEMBL27468730 | 0.83 | CYP1A2 (0.42) | CYP1A2ALDH1A1USP2LMNATSHR | |
| SCHEMBL284683 | 0.79 | SLC6A4 (0.32) | — | |
| SCHEMBL9537043 | 0.78 | CYP1A2 (0.41) | CYP1A2ALDH1A1USP2LMNATSHR | |
| SCHEMBL420260 | 0.78 | CYP1A2 (0.41) | CYP1A2ALDH1A1USP2LMNATSHR | |
| SCHEMBL9537041 | 0.78 | CYP1A2 (0.41) | CYP1A2ALDH1A1USP2LMNATSHR | |
| SCHEMBL283955 | 0.77 | SLC6A4 (0.33) | — | |
| SCHEMBL9301362 | 0.76 | CYP1A2 (0.40) | CYP1A2ALDH1A1USP2LMNATSHR | |
| SCHEMBL11143116 | 0.76 | CYP1A2 (0.40) | CYP1A2ALDH1A1USP2LMNATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120178771-A1 | Oral Pharmaceutical Compositions of Buprenorphine and Method of Use | RELMADA THERAPEUTICS, INC. | 2012-07-12 | — | — | US | disclosed |
| EP-2405754-A1 | MODIFIED RELEASE PHARMACEUTICAL COMPOSITIONS OF BUPRENORPHINE | Theraquest Biosciences, Inc. (US) | 2012-01-18 | — | — | EP | disclosed |
| US-20110097395-A1 | Oral Pharmaceutical Compositions of Buprenorphine and Method of Use | RELMADA THERAPEUTICS, INC. | 2011-04-28 | — | — | US | disclosed |
| EP-2262367-A2 | ORAL PHARMACEUTICAL COMPOSITIONS OF BUPRENORPHINE AND METHOD OF USE | Theraquest Biosciences, Inc. (US) | 2010-12-22 | — | — | EP | disclosed |
| WO-2010104494-A1 | MODIFIED RELEASE PHARMACEUTICAL COMPOSITIONS OF BUPRENORPHINE | THERAQUEST BIOSCIENCES, INC. (US) | 2010-09-16 | — | — | WO | disclosed |
| WO-2009114118-A2 | ORAL PHARMACEUTICAL COMPOSITIONS OF BUPRENORPHINE AND METHOD OF USE | THERAQUEST BIOSCIENCES, INC. (US) | 2009-09-17 | — | — | WO | disclosed |
| WO-2007120485-A2 | METHODS OF TREATING PAIN WITH ALKYLXANTHINES AND ANTIEPILEPTICS AND COMPOSITIONS FOR USE THEREFOR | CINERGEN, LLC (US) | 2007-10-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120178771-A1 | Oral Pharmaceutical Compositions of Buprenorphine and Method of Use | OPRK1, OPRM1, OPRD1 | CYP1A2 16/4885ALDH1A1 388/4885USP2 3448/4885 |
| US-20110097395-A1 | Oral Pharmaceutical Compositions of Buprenorphine and Method of Use | CYP2B6, CYP3A5, OPRM1 | CYP1A2 24/4885ALDH1A1 622/4885USP2 4505/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.